Analyzing Frontline Options for Patients With Bladder Cancer
October 29th 2018Thomas Powles, MD, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.
Watch
Selecting Atezolizumab Plus Bevacizumab Versus Ipilimumab Plus Nivolumab in RCC
October 26th 2018Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses how data should be looked at between 2 combinations for the treatment of renal cell carcinoma. He says atezolizumab plus bevacizumab will never be compared head to head with ipilimumab plus nivolumab.
Watch